Grifols (GRFS) Operating Expenses (2009 - 2023)
Grifols (GRFS) posted Operating Expenses of $171022.8 for Q4 2023, up 364.68% quarter-over-quarter from $36804.4 in Q4 2022, and up 364.68% year-on-year from $36804.4 in Q4 2022.
Grifols (GRFS) Operating Expenses (2009 - 2023) Analysis & Trends
Grifols (GRFS) has reported Operating Expenses for 12 consecutive years, with $171022.8 the latest figure, recorded in Q4 2023.
- Operating Expenses for Q4 2023 came in at $171022.8, up 364.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $207827.2 (changed 0.0% YoY), and the FY2025 annual result was $1.9 billion, up 6.94% from the prior year.
- Operating Expenses was $171022.8 for Q4 2023 at Grifols, up from $36804.4 in the prior quarter.
- Over five years, Operating Expenses peaked at $171022.8 in Q4 2023 and troughed at -$993.1 million in Q4 2019.
- Average Operating Expenses over 4 years is -$336.4 million, with a median of -$337.5 million recorded in 2019.
- Year-over-year, Operating Expenses declined 14.7% in 2019 and surged 364.68% in 2023.
- Over 4 years, Operating Expenses stood at -$993.1 million in 2019, then soared by 64.6% to -$351.5 million in 2020, then soared by 100.01% to $36804.4 in 2022, then soared by 364.68% to $171022.8 in 2023.
- Per Business Quant data, the three most recent Operating Expenses figures were $171022.8 in Q4 2023, $36804.4 in Q4 2022, and -$351.5 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 6.72 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 9.59 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 11.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -8.41 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.82 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 5.95 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.37 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 5.50 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 171,022.80 |
| Dec 31, 2022 | 36,804.40 |
| Mar 31, 2020 | -351.55 Mn |
| Dec 31, 2019 | -993.06 Mn |
| Mar 31, 2019 | -337.55 Mn |
| Dec 31, 2018 | -865.76 Mn |
| Jun 30, 2018 | 305.20 Mn |
| Mar 31, 2018 | -300.11 Mn |
| Dec 31, 2017 | -979.68 Mn |
| Jun 30, 2017 | 303.67 Mn |
| Mar 31, 2017 | -308.10 Mn |
| Dec 31, 2016 | 1.83 Bn |
| Sep 30, 2016 | 254.98 Mn |
| Jun 30, 2016 | 278.46 Mn |
| Dec 31, 2015 | 295.12 Mn |
| Sep 30, 2015 | 261.68 Mn |
| Jun 30, 2015 | 266.77 Mn |
| Mar 31, 2015 | -242.62 Mn |
| Dec 31, 2014 | 270.43 Mn |
| Sep 30, 2014 | 282.82 Mn |